Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review

Journal of Electrocardiology

Volumn 47, Issue 5, 2014, Pages 630-635

  Bang, Casper N ^a,b   Devereux, Richard B ^a   Okin, Peter M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b University of Copenhagen   (Denmark)

Author keywords

Anti hypertensive treatment; Atrial fibrillation; Cardiovascular death; Cardiovascular outcome; Congestive heart failure; Cornell voltage criteria; Hypertension; Left ventricular hypertrophy; Myocardial infarction; Sokolow Lyon criteria; Strain; Stroke

Indexed keywords

ATENOLOL; LOSARTAN; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; ECG ABNORMALITY; ELECTRIC POTENTIAL; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OVEREXERTION; PRIORITY JOURNAL; REVIEW; SYSTOLIC BLOOD PRESSURE; COMPLICATION; ELECTROCARDIOGRAPHY; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; ELECTROCARDIOGRAPHY; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; PROGNOSIS; RISK FACTORS;

EID: 84906937373     PISSN: 00220736     EISSN: 15328430     Source Type: Journal    
DOI: 10.1016/j.jelectrocard.2014.07.003     Document Type: Review

References (27)

1. D. Levy, R.J. Garrison, D.D. Savage, W.B. Kannel, and W.P. Castelli Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study N Engl J Med 322 1990 1561 1566
2. D. Levy, M. Salomon, R.B. D'Agostino, A.J. Belanger, and W.B. Kannel Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy Circulation 90 1994 1786 1793
3. M. Sokolow, and T.P. Lyon The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads Am Heart J 37 1949 161 186
4. P.M. Okin, R.B. Devereux, M.S. Nieminen, S. Jern, L. Oikarinen, and M. Viitasalo et al. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study Circulation 113 2006 67 73
5. P.M. Okin, L. Oikarinen, M. Viitasalo, L. Toivonen, S.E. Kjeldsen, and M.S. Nieminen et al. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE) Circulation 119 2009 1883 1891
6. P.M. Okin, R.B. Devereux, M.S. Nieminen, S. Jern, L. Oikarinen, and M. Viitasalo et al. Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients Hypertension 44 2004 48 54
7. K. Wachtell, P.M. Okin, M.H. Olsen, B. Dahlof, R.B. Devereux, and H. Ibsen et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study Circulation 116 2007 700 705
8. P.M. Okin, K. Wachtell, R.B. Devereux, K.E. Harris, S. Jern, and S.E. Kjeldsen et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension JAMA 296 2006 1242 1248
9. B. Dahlof, R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, and F.U. de et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003
10. P.M. Okin, M.J. Roman, R.B. Devereux, and P. Kligfield Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products J Am Coll Cardiol 25 1995 417 423
11. P.M. Okin, R.B. Devereux, M.S. Nieminen, S. Jern, L. Oikarinen, and M. Viitasalo et al. Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study. Losartan Intervention For End point J Am Coll Cardiol 38 2001 514 520
12. E.W. Hancock, B.J. Deal, D.M. Mirvis, P. Okin, P. Kligfield, and L.S. Gettes et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part V: electrocardiogram changes associated with cardiac chamber hypertrophy: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology J Am Coll Cardiol 53 2009 992 1002
13. B. Dahlof, R.B. Devereux, S. Julius, S.E. Kjeldsen, G. Beevers, and F.U. de et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension Hypertension 32 1998 989 997
14. P.M. Okin, R.B. Devereux, K.E. Harris, S. Jern, S.E. Kjeldsen, and S. Julius et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients Ann Intern Med 147 2007 311 319
15. D.W. Romhilt, and E.H. Estes Jr. A point-score system for the ECG diagnosis of left ventricular hypertrophy Am Heart J 75 1968 752 758
16. P. Verdecchia, G. Schillaci, C. Borgioni, A. Ciucci, R. Gattobigio, and I. Zampi et al. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension J Am Coll Cardiol 31 1998 383 390
17. W.B. Kannel Prevalence and natural history of electrocardiographic left ventricular hypertrophy Am J Med 75 1983 4 11
18. C.T. Larsen, J. Dahlin, H. Blackburn, H. Scharling, M. Appleyard, and B. Sigurd et al. Prevalence and prognosis of electrocardiographic left ventricular hypertrophy, ST segment depression and negative T-wave; the Copenhagen City Heart Study Eur Heart J 23 2002 315 324
19. G.F. Salles, C.R. Cardoso, R. Fiszman, and E.S. Muxfeldt Prognostic significance of baseline and serial changes in electrocardiographic strain pattern in resistant hypertension J Hypertens 28 2010 1715 1723
20. L. Bacharova, V. Szathmary, M. Kovalcik, and A. Mateasik Effect of changes in left ventricular anatomy and conduction velocity on the QRS voltage and morphology in left ventricular hypertrophy: a model study J Electrocardiol 43 2010 200 208
21. P.M. Okin, R.B. Devereux, S. Jern, S.E. Kjeldsen, S. Julius, and M.S. Nieminen et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events JAMA 292 2004 2343 2349
22. K. Wachtell, M. Lehto, E. Gerdts, M.H. Olsen, B. Hornestam, and B. Dahlof et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study J Am Coll Cardiol 45 2005 712 719
23. C.N. Bang, M. Dalsgaard, A.M. Greve, L. Kober, C. Gohlke-Baerwolf, and S. Ray et al. Left atrial size and function as predictors of new-onset of atrial fibrillation in patients with asymptomatic aortic stenosis: the simvastatin and ezetimibe in aortic stenosis study Int J Cardiol 168 2013 2322 2327
24. E. Gerdts, L. Oikarinen, V. Palmieri, J.E. Otterstad, K. Wachtell, and K. Boman et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study Hypertension 39 2002 739 743
25. J.L. Huang, C.T. Tai, J.T. Chen, C.T. Ting, Y.T. Chen, and M.S. Chang et al. Effect of atrial dilatation on electrophysiologic properties and inducibility of atrial fibrillation Basic Res Cardiol 98 2003 16 24
26. B. Neal, S. MacMahon, and N. Chapman Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration Lancet 356 2000 1955 1964
27. P.M. Okin, R.B. Devereux, S. Jern, S.E. Kjeldsen, S. Julius, and M.S. Nieminen et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study Circulation 108 2003 684 690